Betty Pharmaceutical (300558.SZ): Application for clinical trial of postoperative adjuvant treatment indication of high-risk stage IA2-IB after surgery for the Erlotinib Hydrochloride Tablet approved

Zhixin Finance APP News, Beta Pharma (300558.SZ) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA). The company's application for a drug clinical trial for Adiumezumab Hydrochloride Tablets (trade name: Kemina, referred to as "Ertinib") for the indication of postoperative adjuvant therapy for high-risk stage IA2-IB non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene sensitive mutations has been approved by the NMPA.